/ /

  • linkedin
  • Increase Font
  • Sharebar

    Bevacizumab 6-week AMD regimen falls short of ranibizumab 4-week regimen

    Nice, France—Evaluating patients with neovascular age-related macular degeneration (AMD) for treatment every 6 weeks with bevacizumab may be less effective than evaluating them every 4 weeks for treatment with ranibizumab, according to one researcher.

    But the two treatments showed very similar effects in a study presented by Prof. Vivian Wing-Man Ho, of Leighton Hospital, Crewe, United Kingdom, here at the European Society of Retina Specialists 15th EURETINA Congress.

    While both drugs have been shown effective in previous research, bevacizumab is a cancer drug used off label for neovascular AMD while ranibizumab is approved for AMD.

    On the other hand, ranibizumab is more expensive. So clinicians have a keen interest in knowing whether one treatment works better than the other.

    To see how their patients fared on the different regimens, Dr. Ho and her colleagues looked at the records of 102 consecutive patients treated with 1.25 mg intravitreal injections of bevacizumab and 101 consecutive patients treated with 0.5 mg intravitreal injections of ranibizumab between August 2008 and October 2010.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results